Research Paper Volume 12, Issue 24 pp 25101—25119

Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker

Figure 1. Identification of candidate drugs that may treat gastric cancer with high immune activity in TCGA-STAD cohort. (A) Venn diagram (top) showing the number of common candidate drugs (CMap score < -90) from MSI-H (blue) and TMB-H (red) groups via the connectivity map database. Connectivity score table (down) displaying nine common candidate drugs, each row responsible for a drug and columns corresponding to MSI-H and TMB-H groups. The score labels representing the connectivity score of each drug in each group, and right sides of the table indicating the name and mechanism of each drug. These nine drugs can be classified into seven types. (B) GSEA results for candidate drugs based on the functional gene sets of these seven drug types from the Molecular Signatures Database by the function of enricher of clusterprofiler package. Pathways in red font were significantly enriched (p value < 0.05).